BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 30250046)

  • 21. α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity.
    Ghanem SS; Majbour NK; Vaikath NN; Ardah MT; Erskine D; Jensen NM; Fayyad M; Sudhakaran IP; Vasili E; Melachroinou K; Abdi IY; Poggiolini I; Santos P; Dorn A; Carloni P; Vekrellis K; Attems J; McKeith I; Outeiro TF; Jensen PH; El-Agnaf OMA
    Proc Natl Acad Sci U S A; 2022 Apr; 119(15):e2109617119. PubMed ID: 35353605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Skin nerve α-synuclein deposits: a biomarker for idiopathic Parkinson disease.
    Donadio V; Incensi A; Leta V; Giannoccaro MP; Scaglione C; Martinelli P; Capellari S; Avoni P; Baruzzi A; Liguori R
    Neurology; 2014 Apr; 82(15):1362-9. PubMed ID: 24634456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. α-Synucleinopathy phenotypes.
    McCann H; Stevens CH; Cartwright H; Halliday GM
    Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S62-7. PubMed ID: 24262191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potent prion-like behaviors of pathogenic α-synuclein and evaluation of inactivation methods.
    Tarutani A; Arai T; Murayama S; Hisanaga SI; Hasegawa M
    Acta Neuropathol Commun; 2018 Apr; 6(1):29. PubMed ID: 29669601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity.
    Gupta V; Salim S; Hmila I; Vaikath NN; Sudhakaran IP; Ghanem SS; Majbour NK; Abdulla SA; Emara MM; Abdesselem HB; Lukacsovich T; Erskine D; El-Agnaf OMA
    Sci Rep; 2020 May; 10(1):8137. PubMed ID: 32424162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Skin Biopsy May Help to Distinguish Multiple System Atrophy-Parkinsonism from Parkinson's Disease With Orthostatic Hypotension.
    Donadio V; Incensi A; Rizzo G; De Micco R; Tessitore A; Devigili G; Del Sorbo F; Bonvegna S; Infante R; Magnani M; Zenesini C; Vignatelli L; Cilia R; Eleopra R; Tedeschi G; Liguori R
    Mov Disord; 2020 Sep; 35(9):1649-1657. PubMed ID: 32557839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson's disease, multiple system atrophy and dementia with Lewy bodies.
    Van der Perren A; Gelders G; Fenyi A; Bousset L; Brito F; Peelaerts W; Van den Haute C; Gentleman S; Melki R; Baekelandt V
    Acta Neuropathol; 2020 Jun; 139(6):977-1000. PubMed ID: 32356200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phosphorylated NUB1 distinguishes α-synuclein in Lewy bodies from that in glial cytoplasmic inclusions in multiple system atrophy.
    Tanji K; Miki Y; Mori F; Kon T; Kakita A; Takahashi H; Wakabayashi K
    Brain Pathol; 2019 Nov; 29(6):803-812. PubMed ID: 31006160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?
    Fujita M; Sekigawa A; Sekiyama K; Sugama S; Hashimoto M
    J Neurol; 2009 Aug; 256 Suppl 3():286-92. PubMed ID: 19711118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity.
    Price DL; Rockenstein E; Ubhi K; Phung V; MacLean-Lewis N; Askay D; Cartier A; Spencer B; Patrick C; Desplats P; Ellisman MH; Masliah E
    PLoS One; 2010 Nov; 5(11):e14020. PubMed ID: 21103359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy.
    Nimmo JT; Verma A; Dodart JC; Wang CY; Savistchenko J; Melki R; Carare RO; Nicoll JAR
    Alzheimers Res Ther; 2020 Nov; 12(1):159. PubMed ID: 33256825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Associations Between APOE Variants, Tau and α-Synuclein.
    Rodriguez-Vieitez E; Nielsen HM
    Adv Exp Med Biol; 2019; 1184():177-186. PubMed ID: 32096038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploring the putative role of kallikrein-6, calpain-1 and cathepsin-D in the proteolytic degradation of α-synuclein in multiple system atrophy.
    Kiely AP; Miners JS; Courtney R; Strand C; Love S; Holton JL
    Neuropathol Appl Neurobiol; 2019 Jun; 45(4):347-360. PubMed ID: 29993134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Electron Microscopic Analysis of α-Synuclein Fibrils.
    Tarutani A; Hasegawa M
    Methods Mol Biol; 2021; 2322():17-25. PubMed ID: 34043188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alpha-synuclein accumulates in Purkinje cells in Lewy body disease but not in multiple system atrophy.
    Mori F; Piao YS; Hayashi S; Fujiwara H; Hasegawa M; Yoshimoto M; Iwatsubo T; Takahashi H; Wakabayashi K
    J Neuropathol Exp Neurol; 2003 Aug; 62(8):812-9. PubMed ID: 14503637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clusterin/apolipoprotein J is associated with cortical Lewy bodies: immunohistochemical study in cases with alpha-synucleinopathies.
    Sasaki K; Doh-ura K; Wakisaka Y; Iwaki T
    Acta Neuropathol; 2002 Sep; 104(3):225-30. PubMed ID: 12172907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beyond Strains: Molecular Diversity in Alpha-Synuclein at the Center of Disease Heterogeneity.
    Wojewska MJ; Otero-Jimenez M; Guijarro-Nuez J; Alegre-Abarrategui J
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lewy-like aggregation of α-synuclein reduces protein phosphatase 2A activity in vitro and in vivo.
    Wu J; Lou H; Alerte TN; Stachowski EK; Chen J; Singleton AB; Hamilton RL; Perez RG
    Neuroscience; 2012 Apr; 207():288-97. PubMed ID: 22326202
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Parkinson's disease and multiple system atrophy have distinct α-synuclein seed characteristics.
    Yamasaki TR; Holmes BB; Furman JL; Dhavale DD; Su BW; Song ES; Cairns NJ; Kotzbauer PT; Diamond MI
    J Biol Chem; 2019 Jan; 294(3):1045-1058. PubMed ID: 30478174
    [TBL] [Abstract][Full Text] [Related]  

  • 40. α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies: The Way Forward.
    Bellomo G; De Luca CMG; Paoletti FP; Gaetani L; Moda F; Parnetti L
    Neurology; 2022 Aug; 99(5):195-205. PubMed ID: 35914941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.